million phase ii studi price
eloxx issu million share rais gross proce million bring
pro forma cash million eloxx intend initi phase ii studi
mutant cf patient data year may abl treat cf
patient nonsens mutat current address marker leader vertex
overweight cftr modul eloxx also intend initi phase ii studi
cystinosi data earli eloxx present preclin usher syndrom
data ush connect confer juli philadelphia reiter
overweight rate trim price target account dilut
deal
new data ecsf bode clinic start treat cf stabil
defect cftr mrna aris nonsens mutat prevent
nonsense-medi decay mrna possess mutat oral present
organoid data ecf show achiev dose-depend increas
cftr mrna level observ healthi control second oral present
demonstr achiev bioavail healthi volunt singl
cf data cta phase ii cf studi clear belgium
eloxx file ind studi enrol patient
mutat preval nonsens mutat affect cf patient
anticip top-lin phase ii data particip hit-cf help identifi
rare nonsens mutat patient receiv futur
cystinosi data earli eloxx also develop treat cystinosi
ultra-rar lysosom storag diseas mediat nonsens mutat health canada
clear cta begin phase ii studi cystinosi patient
preliminari data earli decreas cystein level white blood cell could
surrog marker clinic benefit
usher syndrom advanc eloxx present preliminari data arvo read-
agent usher syndrom type compani next present preclin
data ush connect confer juli philadelphia
may fail clinic fail gain regulatori approv eloxx may unabl file
ind compani like requir futur fund
eloxx develop drug treat genet diseas caus nonsens mutat
may recent
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
strengthen balanc sheet advanc phase ii
cystic fibrosi cystinosi studi data
eloxx develop small molecul drug treat genet diseas caus nonsens
mutat restor product function protein nonsens mutat also
known prematur termin codon caus earli stop translat
result truncat non-funct protein accord human gene mutat
databas distinct mutat result caus diseas
cystic fibrosi cf cystinosi duchenn muscular dystrophi dmd rett syndrom
mucopolysacchardosi major condit lack disease-
lead candid eukaryot ribosom select glycosid ersg work
select bind human ribosom enabl read stop codon
translat full length function protein importantli also impact
nonsens mediat mrna decay nmd potent mechan induc
degrad mrna well loss function protein strategi enabl small
molecul ersg target divers across numer orphan diseas oppos
singl uniqu mutat adopt gene therapi strategi
eloxx develop cf cystinosi eloxx complet phase ia
singl ascend dose phase ib multipl ascend dose studi subcutan
administ healthi volunt well-toler sae
mild subcutan formul better pharmacokinet intraven
bioavail well linear dose proport auc cmax across
dose cta file approv belgium eloxx file ind
conduct phase ii studi mutant cf patient data estim
cf patient nonsens mutat treat vertex
unmet need competit anticip fda approv cf
global sale billion
cystinosi ultra-rar autosom recess lysosom storag diseas caus
nonsens mutat result accumul amino acid cystin cystagon
procysbi market treat cystinosi expens complianc issu
adult procysbi averag annual price eloxx open ind
begin phase ii proof-of-concept studi cystinosi data earli
forecast global sale million
eloxx platform ersg candid dual mechan amend sever
genet diseas caus nonsens mutat usher syndrom next clinic
program eloxx could begin clinic studi
present preclin data usher syndrom candid ush connect
confer juli philadelphia
initi phase ii studi cf report data
initi phase ii studi cystinosi report data earli
page
reiter overweight rate howev trim price target
roll forward discount period factor dilut
recent offer price target base project enterpris valu
million million
valu cf million appli standard
multipl sale million discount back prior
valu cf million appli multipl sale
million discount back valu cf
europ million appli multipl sale million
discount back prior valu cf europ
million appli multipl sale million discount back
view discount rate appropri could adjust
phase ii cf data later year
valu cystinosi million million
appli multipl sale million discount back
valu cystinosi europ million
million appli multipl sale million discount back
continu add million eloxx preclin usher
syndrom program could enter clinic
eloxx end cash million compani subsequ issu
million share rais gross proce million estim eloxx
hold pro forma cash million million share outstand
januari eloxx borrow million svb westriv thu subtract
project net debt vs previous ad cash
million divid project market cap million million
share arriv price target pleas see exhibit
page
fibrosi market mechan
nmd
nonsens mutat caus prematur termin codon messeng rna
mrna convert sens codon stop codon uag uga
way act stop signal recruit releas factor prematur halt
translat mrna protein result truncat protein product either
inactiv non-funct accord human gene mutat databas
mutat single-point mutat caus prematur stop codon krawczak
et al human mutat known uniqu mutat
human gene equat approxim mutat result
accumul truncat protein toxic mammalian cell adopt
housekeep mechan monitor elimin aberr mrna carri ptc
known nonsens mediat mrna decay nmd nmd trigger presenc
involv complex set interact protein includ upf factor
regul effector upf factor translat termin factor
nmd initi mrna target degrad exonucleas
one approach overcom nonsens mutat translat read-through small
molecul bind ribosom order skip facilit insert cognat
trna carri amino acid allow translat full-length protein howev
suppress alon often suffici produc enough full-length protein
restor biolog function due degrad result mrna nmd
number mrna reduc amount protein produc even via
suppress limit therapeut affect assembl nmd factor
therebi increas number mrna complement suppress
product protein therapeut level pleas exhibit
dual-hit diagram nmd result mrna degrad loss function protein
page
limit activ
aminoglycosid
aminoglycosid antibiot bind bacteri ribosom prevent protein
translat bacteria mammalian cell aminoglycosid bind ribosom
induc conform chang reduc codon-anticodon recognit
weak selectivity/fidel ribosom allow insert cognat trna
carri amino acid region instead releas factor termin
translat thu aminoglycosid act suppressor
howev limit read-through effici toxic limit factor
advanc aminoglycosid read-through therapi select
aminoglycosid bacteri ribosom high dose requir affect eukaryot
ribosom caus kidney tox impact gut bacteri flora addit perman
hear impair report aminoglycosid gentamicin
shown promis suppressor exhibit highest read-through
aminoglycosid despit potenc toxic mammalian cell
ideal therapeut choic
treatment cystic fibrosi patient nonsens mutat
cystic fibrosi cf autosom recess monogen inherit diseas affect
patient world-wide higher preval amongst caucasian although
recent estim suggest preval high patient world-wide
accord cystic fibrosi foundat patient registri cf popul
 estim patient cf caus loss function mutat
cystic fibrosi transmembran conduct regul cftr protein
cftr mutat class type effect approxim cftr
mutat caus cf vast major exceedingli rare import
rememb overlap mutat patient homozyg
copi heterozyg copi given mutat accord cf foundat
patient registri data common mutat account
cf patient includ homozyg heterozyg
split anoth way approxim cf patient make function cftr
reach cell surfac ion channel open patient treatabl
vertex potenti kalydeco ivacaftor bind cftr cell surfac
open ion channel potenti chlorid cl- passag anoth cf
patient produc misfold cftr degrad proteasom reach
cell surfac mutat address vertex orkambi lumacaftor
ivacaftor symdeko tezacaftor ivacaftor fold cftr properli transport
epithelia open cftr cell surfac vertex seek approv
triplerx compris elexacaftor symdeko nda file
ema file treat homozyg first time
heterozyg minim function mutat het/min patient repres
approxim global cf popul
page
remain patient approxim carri nonsens mutat cftr
gene classifi class nonsens mutat current
approv therapi class mutat produc function cftr protein
among class mutat nonsens mutat creat lead truncated/non-
function cftr common mutat includ
current approv therapi address class mutat repres huge
phase ii cystic fibrosi cystinosi data
eukaryot ribosom select glycosid ersg molecul
screen select human ribosom decreas affin bacteri
ribosom unlik first gener suppressor low affin bacteri
ribosom improv safeti profil drug specif decreas mitochondri
tox caus aminoglycosid eloxx propos bind ribosom
rna near site codon-anticodon recognit site stabil trna-mrna
interact junctur result read-through nonsens mutat
restor translat full length protein pleas exhibit addit
modif prevent entri cochlear cell channel
potenti reduc ototox observ aminoglycosid treatment
propos read-through mechan stabil trna-mrna
addit select bind mammalian ribosom potenti
destabil nmd assembl contain mrna one factor play role
initi nmd instabl ribosom movement along mrna translat
brought presenc role stabil kinet
ribosom movement along mrna inhibit could suppress
nucleat nmd slow rate mrna decay result
potenti increas abund ptc-contain mrna two complementari
therapeut properti differenti small molecul previou
page
evid
interrupt
eloxx recent present evid mechan european cystic fibrosi
societi ecf meet interrupt nmd increas product stabl full-
length ptc-contain mrna organoid model cftr mrna contain
analyz use nanostr probe detect end transcript eloxx
assess express cftr mrna organoid harbor heterogen
homogen nonsens mutat includ preval mutat
thought design exploit find cftr probe bind reduc compar
probe due illustr find wild-typ organoid
probe detect detect compar probe detect
detect organoid two nonsens allel heterozyg nonsens
reduc probe detect cftr mrna harbor nonsens mutat
howev organoid treat increas probe bind
observ importantli effect observ organoid model homozyg
heterozyg nonsens mutat pleas exhibit
mediat increas cftr stabil due full length cftr mrna express
increas ratio probe detect nonsens mutat cftr mrna
page
organoid
measur
find consist increas cftr activ observ organoid
swell assay model harbor nonsens mutat
measur forc induc swell new preclin assay assess
activ cftr modul therapi preclin set organoid patient-
deriv cell cultur organoid swell follow administr therapeut
agent specif cell surfac transport cftr drug efficaci
produc function protein organoid swell correl
organoid valid measur clinic respons thu assay indic
function activ mrna contain gener follow exposur read-
agent
key factor whether therapeut effect minimum level
defect cftr protein function restor achiev clinic effect measur
threshold differ among individu estim
normal cftr activ requir clinic benefit eitan et al row et al
eloxx present new organoid analys ecf demonstr abil
induc restor function activ cftr wild type level assay
organoid cultur incub hour result dose
depend vitro swell organoid cultur homozyg
mutat demonstr therapeut activ drug gener
statist signific restor cftr current cell wild type
level pleas exhibit local apic surfac
ad evid restor cftr function swell assay
vitro activ organoid cultur nonsens mutat
north american cystic fibrosi confer nacfc eloxx present
organoid data show swell enhanc addit potenti
corrector vitro data indic cftr activ augment
tripl therapi importantli activ depend presenc nonsens
mutat versu homozyg point select perhap notabl
data increas cftr mrna express dose-depend manner
wild-typ level novel probe assay demonstr transcript express
full-length integr compani also believ could modul nmd
reduc cftr transcript degrad work done character
page
phase sad
mad data
eloxx present impress bodi preclin data across numer
valid assay patient-deriv organoid fact demonstr activ
organoid model genotyp repres top five nonsens mutat
ecf eloxx present complet phase ia singl ascend data seven dose
cohort rang intraven subcutan formul
studi conduct israel belgium random healthi
volunt placebo well-toler sae
mild/moder commonli inject site event treat patient
versu placebo cohort addit includ headach dizzi
ear discomfort evid aberr translat read-through
housekeep gene ototox subcutan administr demonstr high
bioavail well linear dose proport auc cmax across dose
rang mg/kg rout elimin renal
confer eloxx also report preliminari phase ib multipl ascend dose data
six dose cohort rang mg/kg mg/kg twice weekli subcutan
studi conduct belgium random healthi volunt
placebo multipl dose show compar dose-proport auc
cmax data observ singl dose trial observ drug
accumul day pleas exhibit
multipl ascend dose show dose proport plasma pk
phase ii cf data
cta file approv belgium compani file ind
fda eloxx plan phase ii studi twenty-four mutant
cf patient phase ii trial design yet disclos eloxx aim follow
galapago phase ii saphira studi design three dose evalu
intra-pati escal primari endpoint safeti studi measur
sweat chlorid anticip eloxx report phase ii data
importantli patient may organoid elect donat studi
page
particip
februari eloxx announc particip european hit-cf project
organ univers medic center utrecht netherland evalu novel
therapi cf patient rare mutat cf patient rare mutat invit
particip mutat cftr caus cf common
observ least one allel patient next common variant
report popul cff registri go list
mutat becom significantli rarer cf commun long need solut
treat patient hit-cf attempt address challeng deriv organoid
model intestin elig cf patient model predict individu
patient respons therapi base organoid activ patient enrol
appropri clinic studi see eloxx particip hit-cf clear posit
enabl treatment patient rare nonsens mutat
follow phase ii data eloxx hold end phase ii meet fda
present anticip eloxx conduct phase trial
primari endpoint base timelin anticip could gain fda approv
first mutant cf patient europ ultim anticip
approv addit nonsens mutat start project similar price
vertex kalydeco gross net base address patient
popul slight discount europ project sale million
million grow million project european sale
million million reach million equat global
cf sale million million grow billion
 eu cystic fibrosi sale forecast
cf foundat compani report piper jaffray estim
page
unit fibrosi approv nonsens treat sale fibrosi approv nonsens treat sale cf sale advanc phase ii cystinosi studi
eloxx also develop cystinosi ultra-rar autosom recess
lysosom storag diseas cystinosi estim affect live
birth cystinosi multisystem genet disord caus mutat gene
encod lysosom membran transport protein cystinosin cystinosin
respons remov amino acid cystin lysosom mutat
gene result defect cystinosin protein subsequ accumul
lysosom differ organ includ kidney eye liver brain store cystin
poorli solubl form crystal lead tissu organ damag
three major form cystinosi nephropat cystinosi intermedi cystinosi
ocular cystinosi nephropat cystinosi common sever form
account case patient ultim requir kidney transplant
fda approv cystagon cysteamin bitartr follow extend
releas formul procysbi treatment cystinosi adult children
procysbi receiv market author ema approv procysbi
base open-label trial compar extend releas formul immediate-
releas cystagon util white blood cell cystin concentr measur
effect trial demonstr procysbi non-inferior mean
cystin level nmol/mg protein vs nmol/mg protein cystagon
therapi work convert cystin cystein cysteine-cysteamin mix
disulfid exit lysosom via mechan independ defect
cystinosin protein approv two cystin deplet therapi along
improv kidney transplant lifespan patient cystinosi
extend follow administr drug cystin content white
blood cell decreas rapidli requir chronic dose maintain low level
result cystine-deplet agent taken life patient
cystin deplet agent revers kidney dysfunct shown slow
progress kidney damag howev complic cystinosi
abrog cystin deplet agent includ incid primari hypogonad
infertil addit corneal crystal address system
administr requir topic eye drop foul tast smell agent
led complianc issu major issu interrupt lead rapid re-
accumul cystin lead irrevers tissu damag procysbi one
expens approv therapi averag annual price
adult patient remain unmet need therapi address
underli diseas extend life patient
page
studi
vitro studi shown suppress nmd result higher level
accumul patient fibroblast without caus cellular toxic
mous model cystinosi similar result observ administ
mg/kg sc twice week week reduc cystin accumul without
renal toxic valid approach pleas exhibit
vitro efficaci cystinosi
mous model cystinosi similar result observ administ
mg/kg sc twice week week reduc cystin accumul
without renal toxic valid approach pleas exhibit
efficaci cystinosi mice model
page
june eloxx receiv author cta health canada conduct
phase ii studi six cystinosi patient princip investig dr paul
goodyer professor pediatr mcgill univers genom quebec genom
canada provid non-dilut fund estim million million
anticip preliminari proof-of-concept data earli
due ultra-rar cystinosi present anticip could gain fda
approv europ anticip similar respons price cf
estim net net europ upon launch
repres signific discount horizon procysbi project sale
million million grow million project european
sale million million reach million
equat global cf sale million million grow
million pleas exhibit
 eu cystinosi sale forecast
compani report piper jaffray estim
page
unit nonsens patient nonsens treat cystinosi sale nonsens patient nonsens treat cystinosi sale cystinosi sale candid usher syndrom
importantli eloxx screen pool novel esrg compani
present work select new molecul develop genet diseas
caus nonsens mutat arvo eloxx present new data read-
compound model orphan retin diseas usher syndrom eloxx
focus usher syndrom type repres case hear loss
moder vision loss may present adolesc mutat
gene associ type eloxx screen multipl agent treat
condit new data present arvo show dose-depend activ restor
miss protein favor toler pk via intravitr inject eloxx next
provid updat usher syndrom coalit annual confer juli
philadelphia program ind-en studi anticip eloxx could
intellectu properti licens agreement technion
eloxx enter licens agreement technion research
develop foundat trdf israel institut technolog world-wide
exclus right develop commerci technolog relat aminoglycosid
treat human genet diseas caus prematur stop codon eloxx owe trdf pre-
specif mileston royalti product deriv aminoglycosid technolog
mileston payment trdf licens product includ payment
upon first dose patient phase ii clinic studi million upon first dose
patient pivot studi million upon first file nda low-to-mid singl digit
eloxx licens patent applic subsequ patent cooper
treati pct lead compound provid protect
europ japan canada israel composit matter method use use
combin therapi eloxx estim patent protect
eloxx also file patent applic treat genet diseas includ cf
cystinosi dmd ataxia-telengiectasia hurler syndrom hemophilia usher
syndrom tay-sach rett syndrom includ combin therapi exist
treatment cftr modul cf
eloxx file four pct applic gener relat new composit
matter method treat genet diseas recent march
compani file patent applic india relat large-scal manufactur elx-
new compound plan file similar patent issu
patent would expir
page
risk associ eloxx common drug discovery/develop
compani includ clinic regulatori commerci ersg novel class
drug therapeut face multipl regulatori setback may
fail clinic fail gain regulatori approv eloxx could face competit
biotech compani gene therapi and/or gene edit approach
increas awar drug price eloxx may unabl charg premium
price therapi may reach sale project
compani may unabl file ind advanc new therapeut candid
clinic eloxx may unabl sign new collabor eloxx like requir addit
capit eloxx could face futur unforeseen litig may forc defend
rate price target risk
rate june close overweight
price target base non-gaap dilut ep disc
risk includ cf drug may fail clinic gain approv
revenues/profit may meet expect
page
thousand except per share
research develop
gener administr
incom expens
net loss attribut common stockhold
compani report piper jaffray estim
note quarterli result sum annual
current disclosur inform compani found
